{"id":39315,"date":"2022-06-06T19:41:12","date_gmt":"2022-06-06T19:41:12","guid":{"rendered":"https:\/\/harchi90.com\/praxis-nosedives-as-antidepressant-effort-collapses-in-phii-iii-fail-layoffs-to-follow-endpoints-news\/"},"modified":"2022-06-06T19:41:12","modified_gmt":"2022-06-06T19:41:12","slug":"praxis-nosedives-as-antidepressant-effort-collapses-in-phii-iii-fail-layoffs-to-follow-endpoints-news","status":"publish","type":"post","link":"https:\/\/harchi90.com\/praxis-nosedives-as-antidepressant-effort-collapses-in-phii-iii-fail-layoffs-to-follow-endpoints-news\/","title":{"rendered":"Praxis nosedives as antidepressant effort collapses in PhII \/ III fail – layoffs to follow – Endpoints News"},"content":{"rendered":"
\n

In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear.<\/p>\n

None of them needed chemotherapy, radiation, or surgery – the combination that makes up the standard of care for rectal cancer.<\/p>\n

Instead, the patients were treated with a six-month course of dostarlimab, the PD-1 antibody marketed as Jemperli that GSK acquired when it bought Tesaro in 2018. The prerequisite for receiving Jemperli, however, was that patients had early-stage, localized rectal cancer with a rare biomarker known as mismatch repair-deficient (MMR-deficient).<\/p>\n

\n <\/p>\n

Keep reading Endpoints with a free subscription<\/h3>\n

Unlock this story instantly and join 143,400+ biopharma pros reading Endpoints daily – and it’s free. <\/p>\n

\n